دورية أكاديمية
أعرض في EDS

Alprazolam-induced EEG spectral power changes in rhesus monkeys: a translational model for the evaluation of the behavioral effects of benzodiazepines.

التفاصيل البيبلوغرافية
العنوان: Alprazolam-induced EEG spectral power changes in rhesus monkeys: a translational model for the evaluation of the behavioral effects of benzodiazepines.
المؤلفون: Berro LF; Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 N State St, Jackson, MS, 39216, USA. lberro@umc.edu., Overton JS; Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 N State St, Jackson, MS, 39216, USA., Reeves-Darby JA; Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 N State St, Jackson, MS, 39216, USA., Rowlett JK; Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 N State St, Jackson, MS, 39216, USA.
المصدر: Psychopharmacology [Psychopharmacology (Berl)] 2021 May; Vol. 238 (5), pp. 1373-1386. Date of Electronic Publication: 2021 Feb 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7608025 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2072 (Electronic) Linking ISSN: 00333158 NLM ISO Abbreviation: Psychopharmacology (Berl) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin, New York, Springer-Verlag.
مواضيع طبية MeSH: Alprazolam/*pharmacology , Benzodiazepines/*pharmacology , Electroencephalography/*drug effects , Hypnotics and Sedatives/*pharmacology, Animals ; Electromyography ; Electrooculography ; Humans ; Macaca mulatta ; Male ; Sleep/drug effects
مستخلص: Rationale: Benzodiazepines induce electroencephalography (EEG) changes in rodents and humans that are associated with distinct behavioral effects and have been proposed as quantitative biomarkers for GABA A receptor modulation. Specifically, central EEG beta and occipital EEG delta activity have been associated with anxiolysis and sedation, respectively. The extent to which nonhuman primates show the same dose- and topography-dependent effects remained unknown.
Objectives: We aimed at establishing a nonhuman primate model for the evaluation of benzodiazepine EEG pharmacology.
Methods: Four adult male rhesus monkeys were prepared with fully implantable telemetry devices that monitored activity, peripheral body temperature, and contained two EEG (central and occipital), one electromyography (EMG), and one electrooculography channel. We investigated daytime alprazolam-induced changes in EEG spectral power, sleep-wake states, EMG activity, locomotor activity, and body temperature. Alprazolam (0.01-1.8 mg/kg, i.m.) or vehicle was administered acutely, and telemetry recording was conducted for 1 h.
Results: Daytime alprazolam dose-dependently increased central EEG power (including beta activity), increased occipital EEG delta power, and decreased occipital EEG alpha, theta, and sigma power. There was an ~8-fold difference in the potency of alprazolam to increase central EEG beta vs. occipital EEG delta activity (based on relative EEG power). The highest dose, which increased both central EEG beta and occipital EEG delta relative power, induced sedative effects (increased time spent in N1 and N2 sleep stages) and decreased peripheral body temperature and locomotor activity.
Conclusions: Alprazolam induces dose- and topography-dependent EEG changes in rhesus monkeys and provides a valuable model for studying benzodiazepine pharmacology.
References: Eur J Pharmacol. 1991 Nov 26;205(2):213-6. (PMID: 1812012)
Neuropsychobiology. 2007;55(3-4):203-12. (PMID: 17878744)
Pharmacol Biochem Behav. 1990 Apr;35(4):933-6. (PMID: 2161110)
Neuropharmacology. 2004 Aug;47(2):163-74. (PMID: 15223295)
Behav Res Methods. 2005 Aug;37(3):379-84. (PMID: 16405133)
Arch Clin Neuropsychol. 2018 Nov 1;33(7):901-911. (PMID: 29244060)
J Psychopharmacol. 2020 Mar;34(3):348-357. (PMID: 31670615)
Trends Pharmacol Sci. 2018 Aug;39(8):710-732. (PMID: 29903580)
Cereb Cortex. 2004 Jul;14(7):713-20. (PMID: 15054050)
Biol Psychiatry. 1985 Aug;20(8):832-42. (PMID: 2862924)
Biochem Pharmacol. 2011 Jun 15;81(12):1408-21. (PMID: 20937262)
Sleep. 1991 Oct;14(5):464-5. (PMID: 1759100)
Eur Neuropsychopharmacol. 2015 Oct;25(10):1600-10. (PMID: 26195197)
J Med Chem. 2000 Jan 13;43(1):71-95. (PMID: 10633039)
J Neurophysiol. 2015 Jan 1;113(1):116-31. (PMID: 25253471)
Acta Anaesthesiol Scand Suppl. 1990;92:96-102. (PMID: 2109478)
J Pharmacol Toxicol Methods. 2014 Jul-Aug;70(1):86-93. (PMID: 24878255)
Psychopharmacology (Berl). 2006 Jan;184(2):201-11. (PMID: 16378217)
Sleep. 2008 Sep;31(9):1239-50. (PMID: 18788649)
Behav Neurosci. 1993 Dec;107(6):1106-10. (PMID: 8136065)
Eur J Pharmacol. 1990 Aug 28;185(2-3):243-6. (PMID: 1979276)
Acta Anaesthesiol Scand. 1994 Oct;38(7):719-23. (PMID: 7839784)
Neurosci Lett. 2000 Oct 27;293(2):83-6. (PMID: 11027839)
Neurobiol Sleep Circadian Rhythms. 2018 Aug 22;6:9-23. (PMID: 31236518)
Anesthesiology. 1996 Mar;84(3):510-9. (PMID: 8659777)
Biol Psychiatry. 2016 Oct 15;80(8):599-608. (PMID: 26602589)
Handb Clin Neurol. 2018;156:341-351. (PMID: 30454599)
Am J Public Health. 2016 Apr;106(4):686-8. (PMID: 26890165)
Neuropharmacology. 2011 Jun;60(7-8):1042-9. (PMID: 21035473)
Biol Psychiatry. 1992 Sep 1;32(5):438-51. (PMID: 1486149)
Natl Health Stat Report. 2020 Jan;(137):1-16. (PMID: 32510318)
J Pharmacol Toxicol Methods. 2010 Sep-Oct;62(2):95-106. (PMID: 20601019)
Sleep. 1982;5(1):95-105. (PMID: 7071455)
Anesthesiology. 1996 Jan;84(1):64-9. (PMID: 8572355)
Neuropsychobiology. 2001 Jan;43(1):49-53. (PMID: 11150899)
J Pharmacol Exp Ther. 2003 Jan;304(1):88-101. (PMID: 12490579)
Neuropharmacology. 1985 Jan;24(1):69-73. (PMID: 3920546)
Biol Psychiatry. 2012 Jan 15;71(2):154-61. (PMID: 21967958)
Psychopharmacology (Berl). 2020 Apr;237(4):1183-1194. (PMID: 31927603)
Clin EEG Neurosci. 2006 Apr;37(2):66-80. (PMID: 16733939)
Sleep. 2016 Mar 01;39(3):603-12. (PMID: 26943466)
Physiol Rev. 2012 Jul;92(3):1087-187. (PMID: 22811426)
J Comp Neurol. 2020 Oct 15;528(15):2551-2568. (PMID: 32220012)
J Neurosci. 2013 Mar 6;33(10):4494-504. (PMID: 23467365)
Sleep. 2011 Jan 01;34(1):73-81. (PMID: 21203376)
JAMA Intern Med. 2017 Feb 1;177(2):274-275. (PMID: 27942726)
Eval Health Prof. 2003 Sep;26(3):288-314. (PMID: 12971201)
Neuropharmacology. 2015 Jan;88:155-63. (PMID: 25195191)
J Pharmacol Exp Ther. 2018 Jul;366(1):145-157. (PMID: 29720564)
J Clin Monit. 1991 Jul;7(3):259-67. (PMID: 1890449)
Proc Soc Exp Biol Med. 1952 Feb;79(2):261-5. (PMID: 14912089)
Drug Alcohol Depend. 2019 Jul 1;200:95-114. (PMID: 31121495)
PLoS One. 2011 Feb 14;6(2):e16905. (PMID: 21340034)
J Psychopharmacol. 2007 May;21(3):272-82. (PMID: 17591655)
Clin Neurophysiol. 2016 Feb;127(2):1223-1232. (PMID: 26613652)
J Cogn Neurosci. 2013 Oct;25(10):1597-610. (PMID: 23767926)
Appl Physiol Nutr Metab. 2009 Aug;34(4):582-6. (PMID: 19767791)
معلومات مُعتمدة: R01 DA011792 United States DA NIDA NIH HHS; DA049886 United States DA NIDA NIH HHS; DA046778 United States DA NIDA NIH HHS; K99 DA049886 United States DA NIDA NIH HHS; DA011792 United States DA NIDA NIH HHS; R21 DA046778 United States DA NIDA NIH HHS; R01 DA043204 United States DA NIDA NIH HHS; R00 DA049886 United States DA NIDA NIH HHS; DA043204 United States DA NIDA NIH HHS
فهرسة مساهمة: Keywords: Alprazolam; Benzodiazepine; EEG; Rhesus monkey; Sedation; Spectral power
المشرفين على المادة: 0 (Hypnotics and Sedatives)
12794-10-4 (Benzodiazepines)
YU55MQ3IZY (Alprazolam)
تواريخ الأحداث: Date Created: 20210217 Date Completed: 20210519 Latest Revision: 20230531
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8177744
DOI: 10.1007/s00213-021-05793-z
PMID: 33594504
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-2072
DOI:10.1007/s00213-021-05793-z